Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis
- PMID: 25488786
- PMCID: PMC4289210
- DOI: 10.1016/j.berh.2014.10.005
Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis
Abstract
In spondyloarthritis (SpA), spontaneous remission is best described in reactive arthritis, a form of peripheral SpA. Prior SpA observational studies suggested that a significant percentage of patients reached spontaneous remission; however, these patients were followed up under older, broader European Spondyloarthropathy Study Group (ESSG) criteria or were not defined by specific criteria. In general, they were mixed populations of peripheral and axial disease, and the subsets were not differentiated when assessing end points such as remission. There are limited data on the natural history of axial SpA, in part because of the evolution of the criteria with the more recently developed Assessment of SpondyloArthritis International Society (ASAS) criteria, including the designation of non-radiographic axial SpA and peripheral SpA. Clinical trials have been conducted with various remission end points including withdrawal of therapy to determine remission maintenance. The following review addresses the potential for remission in axial and peripheral SpA based on the data from both observational studies and clinical trials.
Keywords: Ankylosing spondylitis; Non-radiographic axial spondyloarthritis; Peripheral spondyloarthritis; Reactive arthritis; Remission; Treatment.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort.Arthritis Rheum. 2013 Dec;65(12):3096-106. doi: 10.1002/art.38140. Arthritis Rheum. 2013. PMID: 23983141
-
Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.Int J Rheum Dis. 2015 Sep;18(7):736-41. doi: 10.1111/1756-185X.12579. Epub 2015 Jul 14. Int J Rheum Dis. 2015. PMID: 26172961
-
Can we reduce the dosage of biologics in spondyloarthritis?Autoimmun Rev. 2013 May;12(7):691-3. doi: 10.1016/j.autrev.2012.08.013. Epub 2012 Aug 23. Autoimmun Rev. 2013. PMID: 22940233 Review.
-
Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.Rheumatology (Oxford). 2016 Nov;55(11):1946-1953. doi: 10.1093/rheumatology/kew230. Epub 2016 Jul 13. Rheumatology (Oxford). 2016. PMID: 27411482 Clinical Trial.
-
Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis.Rheumatology (Oxford). 2020 Nov 1;59(11):3158-3171. doi: 10.1093/rheumatology/keaa268. Rheumatology (Oxford). 2020. PMID: 32696064
Cited by
-
Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort.Rheumatology (Oxford). 2022 Apr 11;61(4):1487-1495. doi: 10.1093/rheumatology/keab565. Rheumatology (Oxford). 2022. PMID: 34270707 Free PMC article.
-
[Tapering and termination of immunosuppressive treatment in spondyloarthritides (including psoriatic arthritis)].Z Rheumatol. 2017 Feb;76(1):21-26. doi: 10.1007/s00393-016-0242-8. Z Rheumatol. 2017. PMID: 27933391 Review. German.
-
The Long-Term Effects of Short-Period Adalimumab Biosimilar Usage in Ankylosing Spondylitis.Cureus. 2023 Mar 20;15(3):e36444. doi: 10.7759/cureus.36444. eCollection 2023 Mar. Cureus. 2023. PMID: 36960229 Free PMC article.
-
Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry.Clin Rheumatol. 2022 Jul;41(7):2053-2063. doi: 10.1007/s10067-022-06145-8. Epub 2022 Mar 30. Clin Rheumatol. 2022. PMID: 35353263
-
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.Arthritis Rheumatol. 2019 Jul;71(7):1101-1111. doi: 10.1002/art.40866. Epub 2019 May 28. Arthritis Rheumatol. 2019. PMID: 30848558 Free PMC article. Clinical Trial.
References
-
- Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25–31. - PubMed
-
- Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–783. - PubMed
-
- van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–368. - PubMed
-
- Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:1369–1374. - PubMed
-
- Bennett AN, McGonagle D, O'Connor P, Hensor EM, Sivera F, Coates LC, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008;58:3413–3418. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials